Search En menu en ClientConnect
Top 5 search results See all results Advanced search
Top searches
Most visited pages


    € 15,000,000
    France : € 15,000,000
    Industry : € 15,000,000
    Signature date(s)
    7/10/2021 : € 15,000,000
    Link to source

    Summary sheet

    Release date
    18 March 2022
    Signed | 07/10/2021
    Project name
    Promoter - financial intermediary
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 15 million
    EUR 67 million

    The Promoter is a French commercial stage innovative medical device company that develops and commercialises a robotic platform to assist surgeons performing complex surgical procedures in a minimally invasive manner.

    The proposed transaction will support research and development (R&D) investments, Clinical and Regulatory spending that are required in order to advance the development of a Computerized Tomography (CT)-guided robotic surgery platform allowing surgeons and interventional radiologists to safely and accurately accomplish percutaneous ablation procedures. It will initially address percutaneous ablation procedures in the liver, with the aim to democratise this minimally invasive treatment to other interventions in the abdomen, and later to other soft tissue organs.

    Additionality and Impact

    The financing of this project addresses the failure in financial markets for RDI, arising from limited access and/or higher cost of financing as a result of factors such as information asymmetries (linked to, and intensified by, the inherent uncertainty of RDI activities, leading to high screening and monitoring costs), misalignment of incentives, lack of collateral and/or lack of track record.

    Through EGF support, the operation addresses the need of financially underserved companies operating in the sector of minimally invasive liver cancer treatments. The contribution to EU policy is therefore significant.

    The EIB's contribution is notable on both the financial and non-financial side. Thanks to the EGF-backing, the EIB may provide stable long-term funding, tailored to meet the expenditures during project implementation by limiting significant cash outflows from the Company in the short to medium term, thereby enabling it to focus on investing in innovation and growth. The venture debt product (equity risk) has a tailor made structure matching the borrower's expected cash flow generation. Thanks to EIB involvement, the borrower may crowd in other financing due to the lower level of perceived risk. The borrower will likewise benefit from the EIB's financial structuring expertise and technical contribution and advice.

    Environmental aspects

    The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

    The Promoter is a private company not operating in the utilities sector and not having the status of a contracting authority; thus, the project is not covered by the EU Directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.


    Quantum Surgical S.A.S. is a French commercial stage innovative medical device company that develops and commercialises a robotic platform to assist surgeons performing complex surgical procedures in a minimally invasive manner.

    Link to source


    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    News & Stories

    Other links


    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications